sRNAlytics: Pioneering Small RNA Biomarker Discovery

PharmaTechOutlook Top 10 Drug Discovery and Development Solution Providers 2018

We’re at an exciting point in history and just scratching the surface of our understanding of biological information embedded within sequencing data. By unlocking the power of small RNAs and combining them with data science, we are enabling the devolopment of new therapeutics that treat the underlying drivers of disease,” exclaims David Salzman, founder of sRNAlytics.

Small RNAs regulate health and disease within all living things. Their expression patterns are conserved across species and can classify tissue and cell type of origin. They are found
in every type of sample and are extremely stable and easy to extract, making them excellent bioanalytical targets. “The exponential increase in research and publications about small RNA reinforces our excitement, but also highlights significant gaps in today’s approach to harness their power,” Salzman adds…

Read Article

AstraZeneca's Incubutor at the Boston BioHub announces on-boarding of sRNAlytics

August 08, 2018
AstraZeneca Pharmaceuticals LP

AstraZeneca’s Incubator at the Boston BioHub is excited to announce the arrival of sRNAlytics, its second company to on-board as a life science incubator resident. As a resident, sRNAlytics will benefit from free access to state-of-the-art laboratory facilities and equipment as well as access to mentoring from AZ and other resident company scientists within the vibrant research hub.

sRNAlytics developed a computational platform that combines Next-Generation Sequencing with big data analytics and machine learning…

Read Article

sRNAlytics to Accelerate its Biomarker Discovery Platform and Services at IndieBio

December 08, 2017
By BioSpace.com Breaking News Staff

Boston, MA and San Francisco, CA: sRNAlytics, an early-stage biotech startup based in Boston who has developed a software platform technology to identify small RNA biomarkers, announced today it will participate in the IndieBio Accelerator Program in San Francisco, CA.

IndieBio is an intensive 4-month business and research accelerator geared towards developing startups with promising, high-impact, technologies. SOSV, the venture capital firm…

Read Article

Massachusetts Startup sRNAlytics Develops Potent Small RNA Biomarker Sequencing Data

August 25, 2017
By Alex Keown, BioSpace.com Breaking News Staff

NEEDHAM, Mass. – When it comes to pharmaceutical drug development, biomarkers play a key role as de-risking tools. Biomarkers can reduce the time it takes to develop drugs, as well as reduce the cost of drug discovery by increasing endpoint data. 

This means biomarkers can play a key role in increasing the amount of money a pharma company can earn over the life of a drug patent. David Salzman, founder and chief executive officer of biomarker startup sRNAlytics, said that can translate into millions of dollars for drug companies..

Read Article